On the Role of Nanocarriers in Oral Drug Delivery
Qin Yu,Wei Wu
DOI: https://doi.org/10.4155/tde-2023-0117
2023-01-01
Therapeutic Delivery
Abstract:Therapeutic DeliveryVol. 14, No. 12 EditorialOn the role of nanocarriers in oral drug deliveryQin Yu & Wei WuQin Yu https://orcid.org/0009-0003-0397-8960Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China & Wei Wu *Author for correspondence: Tel.: +86 21 5198 0084; E-mail Address: wuwei@shmu.edu.cnhttps://orcid.org/0000-0002-0164-0814Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, ChinaCenter for Medical Research & Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Centre, Shanghai, 201399, ChinaKey Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai, 201203, ChinaPublished Online:13 Dec 2023https://doi.org/10.4155/tde-2023-0117AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: bioavailabilitydrug deliverynanocarriersnanomedicineoral absorptionPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Liu Q, Zou J, Chen Z et al. Current research trends of nanomedicines. Acta Pharm. Sin. B 13(11), 4391–4416 (2023).Medline CASGoogle Scholar2. Germain M, Caputo F, Metcalfe S et al. Delivering the power of nanomedicine to patients today. J. Control. Rel. 326, 164–171 (2020).Medline CASGoogle Scholar3. Li Y, Chen N, Palmisano M et al. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations. Mol. Pharm. 12(4), 1308–1317 (2015). • Interesting findings imply that the seemingly 'solutions' are actually micellar particles.Medline CASGoogle Scholar4. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19(2), 125–141 (2001).Medline CASGoogle Scholar5. Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm. 453(1), 215–224 (2013).Medline CASGoogle Scholar6. Mu H, Porsgaard T. The metabolism of structured triacylglycerols. Prog. Lipid Res. 44(6), 430–448 (2005).Medline CASGoogle Scholar7. Mohammad IS, Hu H, Yin L et al. Drug nanocrystals: fabrication methods and promising therapeutic applications. Int. J. Pharm. 562, 187–202 (2019).Medline CASGoogle Scholar8. Chavhan SS, Petkar KC, Sawant KK. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects. Crit. Rev. Ther. Drug Carrier Syst. 28(5), 447–488 (2011).Medline CASGoogle Scholar9. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6(3), 231–248 (2007).Medline CASGoogle Scholar10. Wang D, Jiang Q, Dong Z et al. Nanocarriers transport across the gastrointestinal barriers: the contribution to oral bioavailability via blood circulation and lymphatic pathway. Adv. Drug Deliv. Rev. 203, 115130 (2023). •• A comprehensive review that analyses the in vivo transport pathways for nanocarriers.Medline CASGoogle Scholar11. Chen C, Beloqui A, Xu Y. Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease. Adv. Drug Deliv. Rev. 203, 115117 (2023).Medline CASGoogle Scholar12. Fadaei MR, Mohammadi M, Fadaei MS et al. The crossroad of nanovesicles and oral delivery of insulin. Expert Opin. Drug Deliv. 20(10), 1387–1413 (2023).Medline CASGoogle Scholar13. Deng B, Liu S, Wang Y et al. Oral Nanomedicine: Challenges and Opportunities. Adv. Mater. e2306081 (2023). • A critical review that analyses the status quo and perspectives of oral nanomedicines.MedlineGoogle Scholar14. Liu S, Wen X, Zhang X et al. Oral delivery of biomacromolecules by overcoming biological barriers in the gastrointestinal tract: an update. Expert Opin. Drug Deliv. 20(10), 1333–1347 (2023).Medline CASGoogle Scholar15. Zhang Z, Qi J, Lu Y et al. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm. Sin. B 11(8), 2450–2469 (2021).CASGoogle Scholar16. Ren Y, Wu W, Zhang X. The feasibility of oral targeted drug delivery: gut immune to particulates? Acta Pharm. Sin. B 13(6), 2544–2558 (2023).Medline CASGoogle Scholar17. Zhang Z, Qi J, Lu Y et al. Peroral targeting of drug nanocarriers to sites beyond the gastrointestinal tract. Med. Res. Rev. 41, 2590–2598 (2021). •• Expert opinion that analyses the possibility of nanocarrier-based targeting to sites beyond the gastrointestinal tract.Medline CASGoogle Scholar18. Qi J, Zhuang J, Lv Y et al. Exploiting or overcoming the dome trap for enhanced oral immunization and drug delivery. J. Control. Release 275, 92–106 (2018).Medline CASGoogle Scholar19. Xie Y, Jiang S, Xia F et al. Glucan microparticles thickened with thermosensitive gels as potential carriers for oral delivery of insulin. J. Mater. Chem. B 4(22), 4040–4048 (2016).Medline CASGoogle Scholar20. Xie Y, Hu X, He H et al. Tracking translocation of glucan microparticles targeting M cells: implications for oral drug delivery. J. Mater. Chem. B 4(17), 2864–2873 (2016).Medline CASGoogle ScholarFiguresReferencesRelatedDetails Vol. 14, No. 12 STAY CONNECTED Metrics Downloaded 30 times History Received 14 November 2023 Accepted 29 November 2023 Published online 13 December 2023 Published in print December 2023 Information© 2023 Newlands PressKeywordsbioavailabilitydrug deliverynanocarriersnanomedicineoral absorptionAuthor contributionsQ Yu: writing & revision; WW: conceptualization & revision.Financial disclosureThe authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download